|
|
|
Volumn 2, Issue 4, 2010, Pages 437-
|
|
Phase III clinical trial using daclizumab for relapsing-remitting multiple sclerosis initiated.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DACLIZUMAB;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENT;
MONOCLONAL ANTIBODY;
HUMAN;
MULTIPLE SCLEROSIS;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSIVE AGENTS;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
|
|
EID: 79960562758
PISSN: None
EISSN: 17507448
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (3)
|
|
References (0)
|